Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) entered a 90-day LOI dated March 6, 2026 to acquire a pharmacy distribution network that currently generates approximately €10 million (≈$11.5 million) in annual gross revenue. The network serves broad pharmacy customers in Greece and would integrate with CosmoFarm’s automated logistics to drive efficiencies. The acquisition remains subject to a definitive agreement and customary closing conditions and is presented as part of Cosmos Health’s strategy to help achieve its 2027 revenue guidance of $155.8 million through organic growth and disciplined acquisitions.
Positive
- Adds approximately €10M (~$11.5M) annual gross revenue
- Supports 2027 revenue target of $155.8M
- Expansion of CosmoFarm distribution footprint in Greece
- Potential operating efficiencies via automated logistics integration
Negative
- Acquisition remains subject to execution and customary closing conditions
- LOI term is 90 days, creating short-term transaction uncertainty
News Market Reaction – COSM
On the day this news was published, COSM declined 6.02%, reflecting a notable negative market reaction. Argus tracked a trough of -11.7% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $864K from the company's valuation, bringing the market cap to $13.48M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
COSM was up 4.11% while peers showed mixed moves: SNYR -10.88% (scanner shows +6.87%), ZYXI -37.34%, EDAP +4.49%, YI +1.92%, QIPT 0%. Only one peer appeared in momentum data, pointing to stock-specific drivers.
Previous Crypto,acquisition Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Insider share purchases | Positive | +3.5% | CEO increased stake by 1,466,764 shares, investing over $1.3 million. |
| Jan 21 | Insider share purchases | Positive | +8.5% | CEO bought 647,809 shares, signaling continued commitment to strategy. |
| Jun 18 | Patent rights acquisition | Positive | +4.9% | Agreement to acquire remaining rights to CNS cancer drug patent. |
| Jun 13 | Distribution acquisition | Positive | +3.9% | Completed Pelofarm pharmacy network deal, lifting revenue by over $5M. |
Same-tag news (crypto,acquisition) has seen consistently positive next-day reactions, with all 4 historical events posting gains and an average move of 5.19%.
Over the past two years, Cosmos Health’s crypto,acquisition-tagged news has focused on CEO share accumulation and strategic assets. In June 2024 the company completed Pelofarm’s pharmacy distribution acquisition, expected to lift annual revenue by over $5 million, and agreed to acquire remaining rights to a CNS cancer drug patent. In 2025, two disclosures highlighted substantial insider share purchases exceeding $1.3 million. Today’s LOI for a pharmacy distribution network and reaffirmed $155.8 million 2027 revenue target extend this acquisition-led growth narrative.
Historical Comparison
Past crypto,acquisition news for COSM produced average moves of 5.19%. Today’s LOI and reiterated 2027 revenue target fit the pattern of accretive, growth-focused announcements.
Company has progressed from acquiring pharmacy networks and CNS patent rights to pursuing another sizable distribution network, reinforcing an acquisition-led growth strategy.
Regulatory & Risk Context
An effective Form S-3 filed on 2025-11-07 registers up to $200,000,000 of securities and includes an at-the-market offering of up to $100,000,000 of common stock through A.G.P., with stated use of proceeds including acquisition of crypto assets as a treasury asset and general corporate purposes.
Market Pulse Summary
The stock moved -6.0% in the session following this news. A negative reaction despite the LOI and reaffirmed $155.8 million 2027 revenue target would contrast with prior crypto,acquisition events, which averaged 5.19% gains. Pressure could reflect concerns over execution, integration, or possible use of the $200,000,000 shelf and $100,000,000 ATM. Past patterns showed that even accretive acquisitions sometimes met skepticism when balance sheet or dilution risks were front of mind.
Key Terms
letter of intent financial
loi financial
para-pharmaceutical medical
AI-generated analysis. Not financial advice.
CHICAGO, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has entered into a Letter of Intent (“LOI”), through its wholly owned subsidiary CosmoFarm S.A. (“CosmoFarm”), with respect to the acquisition of an extensive pharmacy distribution network from an established pharmaceutical company serving the Greek market for almost 40 years. The term of the LOI is ninety (90) days from March 6, 2026.
The network currently generates approximately
The acquisition is expected to expand CosmoFarm’s commercial reach and strengthen its distribution footprint. Once integrated into CosmoFarm’s automated logistics platform, which utilizes advanced robotic technologies for procurement, inventory management, and order execution, the network is expected to benefit from improved operating efficiencies and enhanced service levels for pharmacies.
This transaction, which remains subject to the execution of the acquisition agreement containing the customary closing conditions, forms part of the Company’s broader strategy to reach the revenue target for 2027 outlined in its previously announced guidance of
Greg Siokas, CEO of Cosmos Health, stated: "This proposed bolt-on acquisition aligns directly with our strategy of strengthening our core pharmaceutical distribution platform. By expanding our pharmacy network and leveraging our automated infrastructure, we expect to increase scale, improve operating efficiencies, and support continued revenue growth and profitability. We remain focused on disciplined execution and pursuing accretive transactions that create long-term shareholder value. We are actively evaluating additional opportunities and remain confident in our ability to reach the revenue targets set for 2027 under our previously announced guidance.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
